UBS Group’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $227K | Buy |
25,634
+20,114
| +364% | +$178K | ﹤0.01% | 5405 |
|
|
2025
Q1 | $59.4K | Sell |
5,520
-37,694
| -87% | -$406K | ﹤0.01% | 6164 |
|
|
2024
Q4 | $553K | Buy |
43,214
+37,778
| +695% | +$484K | ﹤0.01% | 4626 |
|
|
2024
Q3 | $150K | Buy |
5,436
+1,195
| +28% | +$33K | ﹤0.01% | 4891 |
|
|
2024
Q2 | $123K | Sell |
4,241
-5,718
| -57% | -$166K | ﹤0.01% | 4909 |
|
|
2024
Q1 | $444K | Sell |
9,959
-983
| -9% | -$43.8K | ﹤0.01% | 4184 |
|
|
2023
Q4 | $425K | Buy |
10,942
+1,188
| +12% | +$46.1K | ﹤0.01% | 4085 |
|
|
2023
Q3 | $287K | Buy |
9,754
+2,095
| +27% | +$61.6K | ﹤0.01% | 4004 |
|
|
2023
Q2 | $487K | Sell |
7,659
-3,405
| -31% | -$217K | ﹤0.01% | 3849 |
|
|
2023
Q1 | $522K | Sell |
11,064
-9,487
| -46% | -$448K | ﹤0.01% | 3670 |
|
|
2022
Q4 | $1.43M | Buy |
20,551
+19,535
| +1,923% | +$1.36M | ﹤0.01% | 2850 |
|
|
2022
Q3 | $149K | Buy |
1,016
+755
| +289% | +$111K | ﹤0.01% | 4325 |
|
|
2022
Q2 | $34K | Buy |
261
+11
| +4% | +$1.43K | ﹤0.01% | 5240 |
|
|
2022
Q1 | $25K | Sell |
250
-470
| -65% | -$47K | ﹤0.01% | 6155 |
|
|
2021
Q4 | $112K | Buy |
720
+707
| +5,438% | +$110K | ﹤0.01% | 5147 |
|
|
2021
Q3 | $4K | Buy |
+13
| New | +$4K | ﹤0.01% | 7501 |
|